July 30, 2012
Dainippon Sumitomo Pharma (DSP) announced on July 27 that its US subsidiary, Sunovion Pharmaceuticals Inc., has been granted an additional six months of US market exclusivity for the insomnia treatment Lunesta (eszopiclone). The extended period of market exclusivity will expire...read more